Related Experiment Video
Updated: Aug 4, 2026
08:56
Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis
Published on: February 10, 2015
Phenobarbital effects in cholestatic liver diseases
Annals of Internal Medicine
|March 1, 1975
Summary
Phenobarbital treatment improved bile acid clearance and reduced itching in patients with cholestatic disorders. This suggests phenobarbital may be a beneficial therapy for certain liver conditions.
Area of Science:
- Hepatology
- Pharmacology
Background:
- Cholestatic disorders impair bile acid excretion, leading to liver damage.
- Phenobarbital is a barbiturate with known effects on liver enzymes.
Purpose of the Study:
- To evaluate the efficacy of phenobarbital in treating patients with various cholestatic liver diseases.
- To assess the impact of phenobarbital on liver function tests and clinical symptoms.
Main Methods:
- Fifteen patients with diagnosed cholestatic disorders received phenobarbital for 1-5 months.
- Clinical outcomes, including pruritus, and laboratory parameters (bilirubin, bile acids, BSP, Rose Bengal clearance, cholesterol, alkaline phosphatase, 5'-nucleotidase) were monitored.
Main Results:
- Phenobarbital reduced serum bilirubin and bile acid levels in most patients.
- Hepatic clearance of BSP and Rose Bengal was enhanced, and pruritus improved.
- Alkaline phosphatase and 5'-nucleotidase levels increased, suggesting hepatic origin.
Conclusions:
- Phenobarbital therapy can improve organic anion clearance in patients with cholestatic disorders.
- Phenobarbital may offer therapeutic benefits for select patients suffering from cholestatic liver conditions.
Related Concept Videos
01:19Phase I Reactions: Oxidation of Aliphatic and Aromatic Carbon-Containing Systems
Phase I biotransformation reactions are integral to drug metabolism, predominantly involving oxidative, reductive, and hydrolytic transformations. Chief among these are oxidative reactions, which enhance the hydrophilicity of xenobiotics and introduce polar functional groups to facilitate their elimination from the body.
Oxidation reactions are fundamental in aromatic carbon-containing systems. An example is the hydroxylation of phenobarbital, a process that transforms it into...
Oxidation reactions are fundamental in aromatic carbon-containing systems. An example is the hydroxylation of phenobarbital, a process that transforms it into...
01:16Hepatic Drug Excretion: Influencing Factors
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...